Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock

Key Points

• Insider sale: Brian Adams sold 6,371 Kymera Therapeutics shares for approximately $744,324 to cover tax withholding tied to vested equity awards, reducing his holdings by 11.25% to 50,254 shares.
• Stock performance: KYMR shares rose 0.1% to $117.39, with a market capitalization of approximately $9.76 billion and a 52-week range of $42.22 to $130.05.
• Business outlook: Kymera beat quarterly earnings and revenue expectations, reporting EPS of -$0.62 and revenue of $65 million, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $128.70.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Brian Adams sold 6,371 shares of the business's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the transaction, the insider directly owned 50,254 shares of the company's stock, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Up 0.1%

Shares of NASDAQ KYMR traded up $0.11 during mid-day trading on Friday, reaching $117.39. 378,565 shares of the company were exchanged, compared to its average volume of 733,863. Kymera Therapeutics, Inc. has a 52 week low of $42.22 and a 52 week high of $130.05. The stock has a market capitalization of $9.76 billion, a PE ratio of -36.23 and a beta of 1.96. The company's 50 day moving average price is $113.97 and its 200 day moving average price is $94.74.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million for the quarter, compared to analysts' expectations of $32.78 million. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. The firm's revenue was up 465.2% on a year-over-year basis. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC raised its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after buying an additional 1,083 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock worth $52,000 after buying an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the 4th quarter valued at approximately $63,000.

Analyst Ratings Changes

A number of research analysts have commented on the stock. BTIG Research reiterated a "buy" rating and set a $134.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Citigroup reaffirmed a "buy" rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Bank of America lifted their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Mizuho boosted their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an "outperform" rating in a research note on Thursday, July 16th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Kymera Therapeutics in a research note on Thursday, July 30th. They set a "hold" rating and a $120.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $128.70.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source